...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
【24h】

Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.

机译:股pop动脉再狭窄的抑制:紫杉醇涂层与未涂层球囊:股紫杉醇随机先导试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The success of percutaneous intervention in peripheral arterial disease is limited by restenosis. The aim of the present pilot study was to evaluate a novel method of local drug delivery. METHODS AND RESULTS: This randomized multicenter study with blinded reading enrolled 87 patients in Rutherford class 1 to 4 with occlusion or hemodynamically relevant stenosis, restenosis, or in-stent restenosis of femoropopliteal arteries. Treatment was performed by either conventional uncoated or paclitaxel-coated balloon catheters. The primary end point was late lumen loss at 6 months. Secondary end points included restenosis rate, ankle brachial index, Rutherford class, target lesion revascularization, and tolerance up to >18 months. Before intervention, there were no significant differences in lesion characteristics such as reference diameter (5.3+/-1.1 versus 5.2+/-1.0 mm), degree of stenosis (84+/-11% versus 84+/-16%), proportion of restenotic lesions (36% versus 33%), and mean lesion length (5.7 cm[0.8 to 22.6 cm] versus 6.1 cm [0.9 to 19.3 cm]) between treatment groups. The 6-month follow-up angiography performed in 31 of 45 and 34 of 42 patients showed less late lumen loss in the coated balloon group (0.5+/-1.1 versus 1.0+/-1.1 mm; P=0.031). The number of target lesion revascularizations was lower in the paclitaxel-coated balloon group than in control subjects (3 of 45 versus 14 of 42 patients; P=0.002). Improvement in Rutherford class was greater in the coated balloon group (P=0.045), whereas the improvement in ankle brachial index was not different. The difference in target lesion revascularizations between treatment groups was maintained up to >18 months. No adverse events were assessed as related to balloon coating. CONCLUSIONS: In this pilot trial, paclitaxel balloon coating caused no obvious adverse events and reduced restenosis in patients undergoing angioplasty of femoropopliteal arteries.
机译:背景:经皮介入治疗外周动脉疾病的成功受到再狭窄的限制。本试验研究的目的是评估局部药物递送的新方法。方法和结果:这项随机对照的多中心随机研究纳入了Rutherford 1至4级的87例股pop动脉阻塞或与血流动力学相关的狭窄,再狭窄或支架内再狭窄的患者。通过常规的未涂层或紫杉醇涂层的球囊导管进行治疗。主要终点是6个月时晚期管腔丢失。次要终点包括再狭窄率,踝臂指数,卢瑟福等级,目标病灶血运重建和18个月以上的耐受性。干预前,病变特征无明显差异,例如参考直径(5.3 +/- 1.1对5.2 +/- 1.0 mm),狭窄程度(84 +/- 11%对84 +/- 16%),比例治疗组之间的再狭窄病变的百分比(36%对33%),平均病变长度(5.7 cm [0.8至22.6 cm]对6.1 cm [0.9至19.3 cm])。 45例患者中的31例和42例患者中的34例进行了为期6个月的随访血管造影,结果显示包被的球囊组晚期管腔丢失较少(0.5 +/- 1.1对1.0 +/- 1.1 mm; P = 0.031)。紫杉醇包被的球囊组的目标病变血运重建次数低于对照组(45例中的3例与42例中的14例; P = 0.002)。覆膜球囊组的卢瑟福级改善更大(P = 0.045),而踝臂指数的改善无差异。治疗组之间靶病变血运重建的差异维持至> 18个月。没有不良事件被评估为与球囊覆盖有关。结论:在该试验性试验中,紫杉醇球囊涂层未对股pop动脉血管成形术患者造成明显不良事件并减少了再狭窄。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号